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A B S T R A C T
Background: Precise cause of death (CoD) ascertainment is crucial in any cancer screening trial to avoid
bias from misclassiﬁcation due to excessive recording of diagnosed cancer as a CoD in death certiﬁcates
instead of non-cancer disease that actually caused death. We estimated whether there was bias in CoD
determination between screening (SA) and control arms (CA) in a population-based prostate cancer (PCa)
screening trial.
Methods: Our trial is the largest component of the European Randomized Study of Screening for Prostate
Cancer with more than 80,000 men. Randomly selected deaths in men with PCa (N = 442/2568 cases,
17.2%) were reviewed by an independent CoD committee. Median follow-up was 16.8 years in both arms.
Results: Overdiagnosis of PCa was present in the SA as the risk ratio for PCa incidence was 1.19 (95%
conﬁdence interval (CI) 1.14–1.24). The hazard ratio (HR) for PCa mortality was 0.94 (95%CI 0.82–1.08) in
favor of the SA. Agreement with ofﬁcial CoD registry was 94.6% (k = 0.88) in the SA and 95.4% (k = 0.91) in
the CA. Altogether 14 PCa deaths were estimated as false-positive in both arms and exclusion of these
resulted in HR 0.92 (95% CI 0.80–1.06).
Conclusions: A small differential misclassiﬁcation bias in ascertainment of CoD was present, most likely
due to attribution bias (overdiagnosis in the SA). Maximum precision in CoD ascertainment can only be
achieved with independent review of all deaths in the diseased population. However, this is cumbersome
and expensive and may provide little beneﬁt compared to random sampling.
ã 2016 Elsevier Ltd. All rights reserved.
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Population-based prostate cancer (PCa) screening remains
controversial despite evidence for mortality reduction by the
European Randomized Study of Screening for Prostate Cancer
(ERSPC) [1]. The problem with overdiagnosis of low-risk PCas andAbbreviations: CoD, cause of death; SA, screening arm; CA, control arm; PCa,
prostate cancer; CI, conﬁdence interval; HR, hazard ratio; ERSPC, European
Randomized Study of Screening for Prostate Cancer; PLCO, prostate, lung, colorectal
and ovarian cancer screening trial; PSA, prostate-speciﬁc antigen.
* Corresponding author.
E-mail address: tuomas.kilpelainen@hus.ﬁ (T.P. Kilpeläinen).
http://dx.doi.org/10.1016/j.canep.2016.08.022
1877-7821/ã 2016 Elsevier Ltd. All rights reserved.subsequent overtreatment as well as issues of cost-effectiveness
and quality of life remain to be fully evaluated [2–5].
The Finnish Randomized Study of Screening for Prostate Cancer
is the largest component of the multinational ERSPC trial with over
80, 000 men. The population-based Finnish trial showed a non-
signiﬁcant 15% relative reduction in PCa mortality at 12 years of
follow-up (HR 0.85; 95% conﬁdence interval (CI) 0.69–1.04) [6]. In a
subsequent analysis, non-participation in the screening arm (SA)
was shown to have a major impact on PCa mortality in the Finnish
trial, as correcting for non-participation improved the result into
HR 0.78 (95% CI 0.64–0.96) [7]. A substantial diluting effect may
also be caused by screening contamination (i.e. unorganized
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which remains to be addressed in detail.
A cornerstone in any mortality study is accuracy of data on
causes of death (CoD), and therefore it is customary to establish an
independent CoD review committee to validate these data. Such
review committees have been used both in the ERSPC trial [8] and
Prostate, Lung, Colorectal and Ovarian (PLCO) trial [9]. The Finnish
trial also used a CoD committee that systematically reviewed all
deaths in patients with diagnosed PCa in 1996–2003, blinded in
terms of death certiﬁcate and trial arm. The agreement between
ofﬁcial causes of death and the committee was shown to be
excellent (97.7%; k = 0.95) [10] suggesting reliability of ofﬁcial CoD
statistics in Finland and therefore systematic review was
discontinued. Ofﬁcial CoD data have since been used in mortality
estimates, because reviewing individually all deaths in men with
PCa would be far too laborious, given little improvement over
registered CoD.
The purpose of this study was to analyze whether there was
bias present in CoD ascertainment by trial arm, i.e. differential
misclassiﬁcation that could affect the mortality results. A
secondary purpose was to reassess the level of agreement between
ofﬁcial CoD registry and the random cases reviewed by the CoD
committee.
2. Materials & methods
The Finnish Randomized Study of Screening for Prostate Cancer
is the largest single center of the European Randomized Study of
Screening for Prostate Cancer, with altogether 31 868 (39.8%) men
in the screening arm and 48 299 (60.2%) men in the control arm.
The ERSPC trial is registered (http://registered-trials.com, number
ISRCTN49127736). The trial protocol has been published in detail
previously [6]. To summarize, the men born in 1929–1944 (aged
55–67 years at entry) were identiﬁed from the population registry.
A random sample of 8 000 men was annually allocated to the SA
and the rest of the men in each age group formed the CA. The men
in the CA were not contacted.
The men in the SA were invited to a local clinic for
determination of serum PSA. Men with a PSA 4.0 ng/ml were
referred to a urological clinic for diagnostic examinations including
digital rectal examination, transrectal ultrasound and prostate
biopsy. Men with PSA of 3.0–3.99 ng/ml were referred to an
additional test, which in 1996–1998 was digital rectal examination
and since 1999 determination of the free/total PSA ratio with a cut-
off of 16%. Men with an abnormal additional test were referred for
diagnostic examinations, similar to those with PSA 4.0 ng/ml.
The men were re-invited to the screening test four and eight
years after the ﬁrst screen. Information on PCas detected outside
the screening protocol and in the CA were obtained from the
Finnish Cancer Registry, which has a nearly complete coverage
(99%) of solid cancers diagnosed in Finland [11].
The follow-up ended at death, emigration from Finland or
common closing date, which in this study was December 31st,
2014. All deaths in Finland are registered by Statistics Finland, and
the current 10th revision of the International Classiﬁcation of
Diseases (ICD-10) has been used since 1996.
To validate the quality of ofﬁcial CoD registry, in 1996–2003 all
deaths in men with PCa diagnosis (regardless of the trial arm) were
evaluated by a CoD committee with three members (specialists in
the ﬁelds of urology, forensic pathology and internal medicine).
The members had access to patient records, imaging studies and
medical charts from both hospital records and outpatient clinics.
The members evaluated the reports independently and were
blinded from the ofﬁcial death certiﬁcate information, patient
identity, trial arm and method of cancer detection. In cases ofdisagreement between individual reviewers, a consensus was
sought in joint meetings of the committee.
A ﬂowchart was utilized to estimate the role of underlying PCa
in causing death [8]. The World Health Organization deﬁnes the
underlying CoD as the disease or external injury that initiated the
process that led to death. Treatment complications due to
management of PCa were classiﬁed as PCa deaths according to
the World Health Organization deﬁnition. Altogether 179 cases of
442 underwent autopsy.
PCa mortality and all-cause mortality were estimated using the
Cox proportional hazards regression and Schoenfeld residuals
were used to verify the proportionality assumption. PCa incidence
between trial arms was estimated using Poisson regression with
person-years (the proportionality assumption was violated with
Cox regression in regard to PCa incidence).
The CoD committee was considered the gold standard.
Sensitivity for identifying a PCa death was estimated as the
proportion of correctly identiﬁed PCa deaths (concordance of
ofﬁcial causes with the committee assessment) divided by all PCa
deaths (according to the CoD committee). Speciﬁcity was
calculated as true negatives (non-PCa deaths estimated by ofﬁcial
registry) divided by all those that were non-PCa deaths (based on
the CoD committee review). Positive predictive value was
estimated as the probability that a case labeled as PCa death by
the ofﬁcial registry was indeed correct and negative predictive
value as the probability that a non-PCa death classiﬁed by the
ofﬁcial registry was correct (Table 1). Agreement was estimated by
Cohen’s k statistic [12]. The correcting factor was calculated in
both trial arms separately. The correcting factor was estimated by
dividing the number of actual PCa deaths identiﬁed by the CoD
committee by the number of PCa deaths identiﬁed by ofﬁcial CoD
registry (Table 1). The number of PCa deaths in the SA and CA were
multiplied by this correcting factor to estimate the amount of true
number of PCa deaths in each arm.
Stata 10 (StataCorp, CollegeStation, TX, USA) was used for all
analyses. 95% conﬁdence intervals were used and all statistical
tests were two-sided.
The study protocol was approved by Helsinki and Tampere
University Hospital Ethics committees. Permission to use cancer
registry data was obtained from Research and Development Centre
for Welfare and Health (STAKES, currently National Institute for
Health and Welfare).
3. Results
There were altogether 31 868 men in the SA and 48 299 men in
the CA (Fig. 1). The median follow-up time was 16.8 years in both
arms. A total of 3 587 PCas were diagnosed in the SA (cumulative
incidence 11.3%) and 4 684 (9.7%) in the CA (RR 1.19 with 95% CI
1.14–1.24; p < 0.0001).
At the end of follow-up, 319 (1.0%) men had died of PCa in the SA
and 517 (1.1%) in the CA (PCa mortality HR 0.94 with 95% CI 0.82–
1.08, p = 0.375). Altogether 10 605 (33.3%) men had died of other
causes in the SA and 15 989 (33.1%) in the CA (all-cause mortality
HR 1.01 with 95% CI 0.98–1.03; p = 0.615).
In the SA, there were 1115 (3.5%) men who were diagnosed with
PCa and died of any cause during the follow-up and in the CA
altogether 1 453 (3.0%) such men. Of these deaths, the CoD
committee evaluated 205 (in the SA) and 237 (in the CA) (Table 1).
Overall, the agreement between the CoD committee and ofﬁcial
death certiﬁcates was 95.0%. Based on the cases reviewed by the
CoD committee, there were altogether 7 non-PCa deaths that were
mislabeled by the ofﬁcial records as PCa deaths in the SA (7/
68 = 10.3%) and conversely 4 incorrectly classiﬁed non-PCa deaths
(4/137 = 2.9%) that turned out to be PCa deaths (Table 1). Therefore,
it is estimated that with a correcting factor of 65/68 there should be
Table 1
Crosstabulations of causes of death by ofﬁcial Statistics Finland registry and evaluation of cause of death committee (the gold standard) in the Finnish Randomized Study of
Screening for Prostate Cancer (1996–2014).
Screening arm
Statistics Finland Cause of death committee
Prostate cancer death Other cause of death
Prostate cancer death 61 7 68
Other cause of death 4 133 137
65 140 205
Sensitivity (=61/(61 + 4)) 0.94 (95% CI 0.84–0.98)
Speciﬁcity (=133/(133 + 7)) 0.95 (95% CI 0.90–0.98)
Positive predictive value (=61/(61 + 7)) 0.90 (95% CI 0.79–0.95)
Negative predictive value (=133/(133 + 4)) 0.97 (95% CI 0.92–0.99)
Agreement 94.6%
Expected agreement 56.2%
Kappa 0.88 (95% CI 0.82–0.94)
Correcting factor (=65/68) 0.956
Control arm
Statistics Finland Cause of death committee
Prostate cancer death Other cause of death
Prostate cancer death 105 7 112
Other cause of death 4 121 125
109 128 237
Sensitivity(=105/(105 + 4)) 0.96 (95% CI 0.90–0.99)
Speciﬁcity (=121/(121 + 7)) 0.95 (95% CI 0.89–0.98)
Positive predictive value (=105/(105 + 7)) 0.94 (95% CI 0.87–0.97)
Negative predictive value (=121/(121 + 4)) 0.97 (95% CI 0.92–0.99)
Agreement 95.4%
Expected agreement 50.2%
Kappa 0.91 (95% CI 0.86–0.95)
Correcting factor (=109/112) 0.973
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deaths). Similarly, in the CA, in ofﬁcial statistics there were 7 non-
PCa deaths that had been misclassiﬁed PCa deaths (7/112 = 6.3%)
and 4 PCa deaths that had been misclassiﬁed non-PCa deaths (4/
125 = 3.2%); thus there should be 517*(109/112) = 503 PCa deaths in
the CA (i.e. altogether 14 fewer PCa deaths). When the presumably
false positive PCa deaths (N = 14) were excluded from the SA and
from the CA (N = 14), the resulting HR was 0.92 (95% CI 0.80–1.06;
p = 0.267).
Inter-observer agreement was 94.6% in the SA (k = 0.88) and
95.4% in the CA (k = 0.91). There were no essential differences in
sensitivity, speciﬁcity, positive predictive value or negative
predictive value between the trial arms (Table 1).Fig. 1. A CONSORT-style ﬂow chart of the Finnish RandomizThe most common CoD in the trial were diseases of the
circulatory system and cancer (Table 2). The CoD distribution was
equal between trial arms and no statistically signiﬁcant differences
were observed (results not shown). Altogether four cases were
identiﬁed as intervention-related PCa deaths, and two of these
were missed by death certiﬁcates (both were from the SA).
4. Discussion
In any trial with disease-speciﬁc mortality as an endpoint,
causes of death must be determined as precisely as possible to
avoid bias. Particular concern is differential misclassiﬁcation,
which means that the mortality results are not comparableed Study of Screening for Prostate Cancer (1996–2014).
Table 2
Cause of death distribution in the Finnish Randomized Study of Screening for Prostate cancer (1996–2014) according to ICD-10 classiﬁcation.
Cause of death Control arm Screening arm Total
N (%) N (%)
Infectious diseases (A00-B99) 135 (0.8) 82 (0.8) 217
Prostate cancer (C61) 517 (3.1) 319 (2.9) 836
Other urological cancers (C60-68, not C61) 317 (1.9) 202 (1.8) 519
Other cancers (C00-C96, not C60-C68) 4163 (25.2) 2755 (25.2) 6918
Benign tumours (D10-36) 8 (0.0) 11 (0.1) 19
Unknown tumours (D37-48) 57 (0.3) 44 (0.4) 101
Diseases of the blood and blood-forming organs (D50-89) 18 (0.1) 6 (0.1) 24
Endocrine, nutritional and metabolic diseases (E00-E90) 212 (1.3) 142 (1.3) 354
Mental and behavioural disorders (F00-F99) 339 (2.1) 219 (2.0) 558
Diseases of the nervous system (G00-G99) 980 (5.9) 685 (6.3) 1665
Diseases of the circulatory system (I00-I99) 6456 (39.1) 4208 (38.5) 10,664
Diseases of the respiratory system (J00-J99) 1001 (6.1) 719 (6.6) 1720
Diseases of the digestive system (K00-K93) 873 (5.3) 583 (5.3) 1456
Diseases of the skin (L00-L99) 12 (0.1) 4 (0.0) 16
Diseases of the musculoskeletal system (M00-M99) 51 (0.3) 33 (0.3) 84
Diseases of the genitourinary system (N00-N99) 68 (0.4) 46 (0.4) 114
Congenital illnesses and abnormalities (Q00-Q99) 16 (0.1) 9 (0.1) 25
Symptoms and signs of abnormalilies (R00-R99) 111 (0.7) 72 (0.7) 183
Injury, poisoning or other external cause (S00-T98) 1172 (7.1) 785 (7.2) 1957
16,506 (100.0) 10,924 (100.0)
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study shows that some differential bias was present in the Finnish
Randomized Study of Screening for Prostate Cancer, but this is
unlikely to cause substantial error in PCa mortality. At a median
16.8 years of follow-up, the uncorrected PCa mortality HR was 0.94
(95% CI 0.82–1.08) in favor of screening and with CoD correction,
the HR improved to 0.92 (0.80–1.06).
Biases that can cause differential misclassiﬁcation in cancer
screening trials have been divided into two types [13]. Attribution
bias (so-called “sticky diagnosis” bias) is caused by the fact that in
the intervention (screening) arm more cancers are diagnosed and
subsequently it is more probable that deaths in the screened
population are attributed to the particular cancer than in the
control population, as a previous diagnosis may be entered into the
death certiﬁcate even if this disease does not initiate the chain of
events that causes death. Attribution bias exaggerates cancer-
speciﬁc mortality in the screening arm and hence underestimates
the mortality reduction.
A bias in the opposite direction results from the increased
diagnostic testing within the screening arm and subsequent
treatment that may result in death. If the fundamental role of
screening, diagnostic testing or treatment for screen-detected
cancer in inducing the death is not recognized and recorded
appropriately, a slippery-linkage bias occurs. Slippery-linkage bias
underestimates the cancer-speciﬁc mortality in the screening arm.
Both of these biases may be avoided by using all-cause
mortality as an endpoint. However, this would require an
extremely large cancer screening trial or an unrealistically large
screening impact to show any statistical difference between the
trial arms, because any speciﬁc cancer type causes of a small
fraction of all deaths in the population. Despite potential biases,
cancer-speciﬁc mortality is generally more informative than all-
cause mortality in screening trials. The biases with cancer-speciﬁc
mortality can be minimized by using an independent CoD review
board that is blinded to the screening status of the deceased
[8,9,13]. However, blinding is not always complete as the members
of the CoD committee may be able to recognize the screening
status from medical records [14].
In Finland, medical doctors are obliged by law to issue a death
certiﬁcate, when a person dies. That is why the coverage of death
certiﬁcates is near 100%. A copy of this certiﬁcate is ﬁrst reviewed
by forensic experts at the ofﬁces of the National Institute for Health
and Welfare after which they are submitted to Statistics Finland,which maintains the ofﬁcial CoD registry, or returned for re-
issuing. Death certiﬁcates are accepted to the ofﬁcial registry or
modiﬁed according to the WHO guidelines. An estimated 1.4% of
death certiﬁcates require further clariﬁcation by the issuing
medical doctor [15]. Roughly a third of the deceased undergo an
autopsy in Finland [16].
In the Finnish trial, all deaths in men with diagnosed PCa were
reviewed by our CoD committee in 1996–2003 and outstanding
agreement (97.7%; k = 0.95) was observed between the review
committee and ofﬁcial CoD registry. As the Finnish screening trial
is very large and the number of deaths in men with PCa exceeded
2500, all cases could not be reviewed individually. After 2003, only
randomly selected deaths (N = 127) have been reviewed by the
committee.
The current study shows agreement of 94.6% (k = 0.88) in the SA
and 95.4% (k = 0.91) in the CA. The agreement is slightly inferior to
that previously published, but is still excellent. The Rotterdam
section of the ERPSC trial reported a relatively good agreement of
90.6% (k = 0.76) [17]. Later, the Swedish section reported agree-
ment of 97.3% (k = 0.94) in the SA and 94.7% (k = 0.89) in the CA
[18]. The other centers of the ERSPC trial have hitherto not
published separate agreement results regarding CoD ascertain-
ment. The PLCO trial recently reported an excellent agreement
between death certiﬁcates and PLCO death review committee:
97.2% in the SA (k = 0.88) and 96.5% in the CA (k = 0.87) [9].
A possible reason for a decline in agreement is that the trial
population has become older and has accrued more comorbidities
or malignancies that complicate assigning the underlying CoD. In a
prospective trial, it may be beneﬁcial in terms of cost-effectiveness
to assess the comorbidity load of the deceased (especially if there
are multiple malignancies present) to aid selection of cases for CoD
committee review.
This study shows that the ofﬁcial CoD registry is likely to
overestimate the role of prostate cancer in both trial arms, but
slightly more (7.4%) in the screened population than in the CA
(3.1%). Such overestimation, most likely due to the aforementioned
attribution bias, dilutes the mortality reduction by screening. After
correcting for this attribution bias, the HR of PCa death decreased
slightly from 0.94 (0.82–1.08) to 0.92 (0.80–1.06).
A limitation in this study is that we have not reviewed all the
deaths in men with PCa (roughly 2500) to fully ascertain the
underlying causes of death. Instead, we used random sampling
(altogether 442 deaths) to estimate the magnitude of
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non-organized PSA-testing) is likely to cause some degree of
attribution bias also in the CA.
5. Conclusions
There appears to be a small but real differential misclassiﬁca-
tion bias in the Finnish Randomized Study of Screening for Prostate
Cancer. This is probably caused by attribution bias as the screened
men are more likely to be diagnosed with PCa. The PCa diagnosis
can eventually be recorded as an ofﬁcial underlying CoD, even
when the chain of events leading to death is ultimately caused by
another disease. In any screening trial with disease-speciﬁc
mortality as an end-point, this attribution bias should preferably
be controlled with reviewing all deaths in those diseased to
maximize precision, although the beneﬁt may remain minimal.
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